Mark Ashby

4.2k total citations · 2 hit papers
45 papers, 2.9k citations indexed

About

Mark Ashby is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Ashby has authored 45 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Ashby's work include Hematopoietic Stem Cell Transplantation (11 papers), Platelet Disorders and Treatments (7 papers) and Polyomavirus and related diseases (4 papers). Mark Ashby is often cited by papers focused on Hematopoietic Stem Cell Transplantation (11 papers), Platelet Disorders and Treatments (7 papers) and Polyomavirus and related diseases (4 papers). Mark Ashby collaborates with scholars based in United States, Australia and South Korea. Mark Ashby's co-authors include Virginia Paton, Andrew D. Seidman, Stanford J. Stewart, Clifford A. Hudis, Mary Kathryn Pierri, Steven Shak, Maureen Murphy, Deborah Keefe, Mark Kozloff and Axel Grothey and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark Ashby

44 papers receiving 2.8k citations

Hit Papers

Cardiac Dysfunction in th... 2002 2026 2010 2018 2002 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
    2002 1.1k citations Mark Ashby et al. profile →
  2. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy
    2013 392 citations Allen P. Kaplan, Dennis K. Ledford et al. Journal of Allergy and Clinical Immunology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark Ashby 1.3k 766 500 428 410 45 2.9k
Ruth Ladenstein 1.3k 1.1× 386 0.5× 1.4k 2.9× 378 0.9× 342 0.8× 204 5.5k
Ephraim P. Hochberg 1.9k 1.5× 236 0.3× 410 0.8× 1.2k 2.8× 140 0.3× 148 5.2k
Siegal Sadetzki 582 0.5× 121 0.2× 553 1.1× 249 0.6× 111 0.3× 95 3.9k
Valerie Miké 865 0.7× 121 0.2× 739 1.5× 172 0.4× 297 0.7× 40 2.4k
Iyad Sultan 941 0.7× 257 0.3× 1.3k 2.5× 55 0.1× 336 0.8× 126 3.1k
Noah Federman 1.0k 0.8× 153 0.2× 1.3k 2.7× 118 0.3× 474 1.2× 142 3.0k
Daniel Albo 1.8k 1.4× 315 0.4× 753 1.5× 64 0.1× 78 0.2× 91 4.1k
Marie José Kersten 2.1k 1.7× 186 0.2× 242 0.5× 1.1k 2.5× 87 0.2× 255 4.7k
Emily C. Zabor 1.6k 1.2× 263 0.3× 1.2k 2.4× 56 0.1× 148 0.4× 171 4.7k

Countries citing papers authored by Mark Ashby

Since Specialization
Citations

This map shows the geographic impact of Mark Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ashby more than expected).

Fields of papers citing papers by Mark Ashby

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ashby. The network helps show where Mark Ashby may publish in the future.

Co-authorship network of co-authors of Mark Ashby

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Ashby. A scholar is included among the top collaborators of Mark Ashby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Ashby. Mark Ashby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morgan, Forrest, et al.. (2020). Military Applications of Artificial Intelligence: Ethical Concerns in an Uncertain World. RAND Corporation eBooks. 50 indexed citations
2.
Rigby, William F. C., et al.. (2013). Safety of Rituximab in Combination with Other Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: An Open-label Study. The Journal of Rheumatology. 40(5). 599–604. 23 indexed citations
3.
Kaplan, Allen P., Dennis K. Ledford, Mark Ashby, et al.. (2013). Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. Journal of Allergy and Clinical Immunology. 132(1). 101–109. 392 indexed citations breakdown →
4.
Kabbinavar, Fairooz F., Patrick J. Flynn, Mark Kozloff, et al.. (2012). Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study. European Journal of Cancer. 48(8). 1126–1132. 41 indexed citations
5.
Tebbi, Cameron K., John J. Costanzi, Robert J. Shulman, et al.. (2011). A Phase III, Open-Label, Single-Arm Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters. Journal of Vascular and Interventional Radiology. 22(8). 1117–1123. 8 indexed citations
6.
Kozloff, Mark, Jordan Berlin, Patrick J. Flynn, et al.. (2010). Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study. Oncology. 78(5-6). 329–339. 94 indexed citations
7.
Gabrail, Nashat, Eric Sandler, Veena Charu, et al.. (2010). TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters. Journal of Vascular and Interventional Radiology. 21(12). 1852–1858. 12 indexed citations
8.
Luskin, Allan T., Mark Kosinski, Brian W. Bresnahan, Mark Ashby, & Dennis A. Wong. (2005). Symptom Control and Improved Functioning: The Effect of Omalizumab on Asthma-Related Quality of Life (ARQL). Journal of Asthma. 42(10). 823–827. 10 indexed citations
9.
Corren, Jonathan, Thomas B. Casale, Yamo Deniz, & Mark Ashby. (2003). Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. Journal of Allergy and Clinical Immunology. 111(1). 87–90. 142 indexed citations
10.
Linker, Charles, Paolo Anderlini, Roger H. Herzig, et al.. (2003). Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biology of Blood and Marrow Transplantation. 9(6). 405–413. 24 indexed citations
11.
Gajewski, James, Gabriela Rondón, Michèle L. Donato, et al.. (2002). Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biology of Blood and Marrow Transplantation. 8(10). 550–556. 11 indexed citations
12.
Nash, Richard A., Razelle Kurzrock, John F. DiPersio, et al.. (2000). A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 6(1). 25–34. 67 indexed citations
13.
Jones, Dennie V., et al.. (1998). Recombinant human thrombopoietin clinical development. Stem Cells. 16(S1). 199–206. 5 indexed citations
14.
Lindsay, William R., et al.. (1997). A comparison of the effects of four therapy procedures on concentration and responsiveness in people with profound learning disabilities. Journal of Intellectual Disability Research. 41(3). 201–207. 30 indexed citations
15.
Eron, Joseph J., Mark Ashby, Marlene Chernow, et al.. (1996). Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. The Lancet. 348(9041). 1547–1551. 54 indexed citations
16.
Atkinson, K, J. C. Biggs, A Concannon, et al.. (1993). Changing results of HLA‐identical sibling bone marrow transplantation in patients with haematological malignancy during the period 1981–1990. Australian and New Zealand Journal of Medicine. 23(2). 181–186. 4 indexed citations
17.
18.
Campana, F., Alain Fourquet, Mark Ashby, et al.. (1989). Presentation of axillary lymphadenopathy without detectable breast primary (T0 Nib breast cancer): experience at Institut Curie. Radiotherapy and Oncology. 15(4). 321–325. 42 indexed citations
19.
20.
Atkinson, K, et al.. (1988). HIGH INCIDENCE OF EARLY LEUKEMIC RELAPSE IN PATIENTS GIVEN CYCLOSPORIN AND T CELL DEPLETED HLA‐IDENTICAL SIBLING MARROW TRANSPLANTS FOR ACUTE LEUKEMIA IN FIRST REMISSION*. Australian and New Zealand Journal of Medicine. 18(4). 587–593. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruth Ladenstein Breakdown of academic impact, for papers by Ephraim P. Hochberg Breakdown of academic impact, for papers by Siegal Sadetzki Breakdown of academic impact, for papers by Valerie Miké Breakdown of academic impact, for papers by Iyad Sultan Breakdown of academic impact, for papers by Noah Federman Breakdown of academic impact, for papers by Daniel Albo Breakdown of academic impact, for papers by Marie José Kersten Breakdown of academic impact, for papers by Emily C. Zabor
Rankless by CCL
2026